This Core serves two functions. The first is to provide a service to other TCORS investigators by carrying out the analysis of biofluid samples for their studies. The second is to develop new biomarkers of exposure that can be applied to the studies carried out by TCORS investigators, as well as to advance the field. Our laboratory is able to measure alkaloids and toxic substances in both tobacco products and in tobacco smoke. These measurements are needed for biomarker development and to interpret the biomarker data for distinguishing smokeless from smoked tobacco use. These measurements will include other substances in order to explore relationships between toxins and toxin precursors in tobacco and smoke with exposure determined using biomarkers. The improved exposure assessment measures that we expect to develop, and their application to studies carried out by the TCORS, could serve as models for future studies of the risks of new tobacco products and provide scientific basis for their regulation.

Public Health Relevance

The development and validation of biomarkers is a high priority issue for FDA regulation. Studies of tobacco product chemistry with biomarker analyses may provide information on which substances are associated with toxin exposure in humans. Precursors in smoking products that generate toxic substances might provide leads for reducing the toxicity of new products or be targets for regulation. We expect that our studies will result in improved methods for determining human exposure to toxic substances in tobacco and tobacco smoke.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA180890-02
Application #
8754525
Study Section
Special Emphasis Panel (ZRG1-BDCN-A)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
2
Fiscal Year
2014
Total Cost
$378,787
Indirect Cost
$138,649
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Watkins, Shannon Lea; Glantz, Stanton A; Chaffee, Benjamin W (2018) Noncigarette Tobacco Products-Gateway or Diversion?-Reply. JAMA Pediatr 172:784-785
Kim, Minji (2018) Philip Morris International introduces new heat-not-burn product, IQOS, in South Korea. Tob Control 27:e76-e78
Goldberg, Rachel L; Cataldo, Janine K (2018) Marijuana and Prescription Pain Reliever Use among Cigarette Smokers. J Psychoactive Drugs 50:339-347
Elias, Jesse; Hendlin, Yogi; Chaffee, Benjamin W et al. (2018) Don't throw smokeless tobacco users under the bus. Addict Behav 77:289-290
Wang, Lanqing; Bernert, John T; Benowitz, Neal L et al. (2018) Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. Cancer Epidemiol Biomarkers Prev 27:1083-1090
Chaffee, Benjamin W; Cheng, Jing (2018) Cigarette and Smokeless Tobacco Perception Differences of Rural Male Youth. Tob Regul Sci 4:73-90
Wang, Yingning; Sung, Hai-Yen; Yao, Tingting et al. (2018) Health Care Utilization and Expenditures Attributable to Cigar Smoking Among US Adults, 2000-2015. Public Health Rep 133:329-337
Gotts, Jeffrey E; Chun, Lauren; Abbott, Jason et al. (2018) Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 315:L25-L40
Max, Wendy B; Sung, Hai-Yen; Lightwood, James et al. (2018) Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product. Tob Control 27:s82-s86
Sung, Hai-Yen; Wang, Yingning; Yao, Tingting et al. (2018) Polytobacco Use and Nicotine Dependence Symptoms Among US Adults, 2012-2014. Nicotine Tob Res 20:S88-S98

Showing the most recent 10 out of 101 publications